Skip to content

A study to evaluate the effect of extracorporeal shock wave therapy for chronic body pain in patients attending a palliative care outpatient clinic

Evaluation of the usefulness of extracorporeal shock wave therapy(ESWT) for chronic secondary musculoskeletal pain in patients attending a palliative care outpatient clinic - ESWT-Palliative study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059476
Enrollment
20
Registered
2025-12-25
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic secondary musculoskeletal pain

Interventions

After diagnosis of chronic secondary musculoskeletal pain by the attending physician, written informed consent will be obtained by the investigator. The investigator will then determine the treatment

Sponsors

Saitama Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age, sex, and underlying disease are not limited. Patients diagnosed with chronic secondary musculoskeletal pain during outpatient visits. Patients who have provided consent to receive extracorporeal shock wave therapy (ESWT). Patients who have provided consent to participate in the study. In cases where the patient is unable to sign due to any reason, verbal consent or proxy consent will be accepted.

Exclusion criteria

Exclusion criteria: Patients whom the investigator judges to be inappropriate for inclusion in the study. Patients with any lesion (e.g., malignant tumor, metastasis, or fracture) within 5 cm of the planned ESWT treatment site. Patients who develop skin disorders of CTCAE Grade 2 after ESWT. Patients who refuse ESWT after enrollment. Patients with severe cognitive impairment or psychiatric disorders that make appropriate evaluation difficult. Patients with a high risk of bleeding, such as those with coagulation disorders or taking anticoagulant medications. Patients with cardiovascular devices (e.g., pacemaker) located at or near the planned treatment site. Patients with local infection or purulent lesions at the planned treatment site. Patients who are pregnant or may be pregnant. Patients with severe osteoporosis who have an extremely high risk of fracture.

Design outcomes

Primary

MeasureTime frame
Change in pain intensity assessed by the Numerical Rating Scale (NRS) before and after ESWT.

Secondary

MeasureTime frame
Change in range of motion (ROM)

Countries

Japan

Contacts

Public Contactsuga kentaro

Saitama Medical University Hospital palliative care team

suga.kentaro@1972.saitama-med.ac.jp0492761111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026